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ABSTRACT
SWI/SNF complexes utilize BRG1 (also known as SMARCA4) or BRM (also 
known as SMARCA2) as alternative catalytic subunits with ATPase activity to remodel 
chromatin. These chromatin-remodeling complexes are required for mammalian 
development and are mutated in ~20% of all human primary tumors. Yet our 
knowledge of their tumor-suppressor mechanism is limited. To investigate the role 
of SWI/SNF complexes in the DNA-damage response (DDR), we used shRNAs to 
deplete BRG1 and BRM and then exposed these cells to a panel of 6 genotoxic agents. 
Compared to controls, the shRNA knockdown cells were hypersensitive to certain 
genotoxic agents that cause double-strand breaks (DSBs) associated with stalled/
collapsed replication forks but not to ionizing radiation-induced DSBs that arise 
independently of DNA replication. These findings were supported by our analysis 
of DDR kinases, which demonstrated a more prominent role for SWI/SNF in the 
activation of the ATR-Chk1 pathway than the ATM-Chk2 pathway. Surprisingly, γH2AX 
induction was attenuated in shRNA knockdown cells exposed to a topoisomerase II 
inhibitor (etoposide) but not to other genotoxic agents including IR. However, this 
finding is compatible with recent studies linking SWI/SNF with TOP2A and TOP2BP1. 
Depletion of BRG1 and BRM did not result in genomic instability in a tumor-derived 
cell line but did result in nucleoplasmic bridges in normal human fibroblasts. Taken 
together, these results suggest that SWI/SNF tumor-suppressor activity involves a 
role in the DDR to attenuate replicative stress and genomic instability. These results 
may also help to inform the selection of chemotherapeutics for tumors deficient for 
SWI/SNF function.
INTRODUCTION
In eukaryotic cells, genomic DNA is packaged as 
chromatin, and the nucleosome is the most fundamental 
unit. Although nucleosomes help compact the genome 
and maintain its organization, they are an impediment 
to transcription, DNA replication, and DNA repair. To 
counteract nucleosomes and facilitate these essential 
processes, SWI/SNF chromatin-remodeling complexes 
have been evolutionarily conserved from yeast to 
humans [1–3]. Recruited by pioneer transcription 
factors to specific sites in the genome, SWI/SNF 
utilizes the energy of ATP hydrolysis to slide or evict 
nucleosomes [1–3].
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Mammalian SWI/SNF complexes utilize either 
BRG1 (also known as SMARCA4) or BRM (also known 
as SMARCA2) as alternative catalytic subunits with DNA-
dependent ATPase activities and contain 8–11 additional 
subunits (often referred to as BAFs) [1–3]. Based on 
gene-targeting experiments in mice, SWI/SNF complexes 
are required for embryonic development [2, 3]. SWI/
SNF complexes are important for human development 
as well. For example, BRG1 and BRM mutations (as well 
as BAF250A/ARID1A and BAF250B/ARID1B mutations) 
are responsible for Coffin-Siris and Nicolaides-Baraitser 
syndromes which have similar phenotypic spectrums that 
include intellectual disability, altered craniofacial features, 
and distal limb anomalies [4–6]. These mutations occur de 
novo and are heterozygous, which implies that these SWI/
SNF subunits are extremely dosage sensitive.
SWI/SNF complexes also function as tumor 
suppressors based on somatic, loss-of-function mutations 
in human tumors [7]. Exome-sequencing projects 
consistently identify recurrent SWI/SNF mutations in 
primary human tumors of diverse origin. Meta-analyses 
of these data indicate that ~20% of all human tumors 
have a mutation in SWI/SNF, which is among the highest 
incidence of any tumor suppressor and approaches the 
TP53 mutation frequency of 26% [8, 9]. The majority 
of SWI/SNF mutations occur in the BRG1/SMARCA4 
catalytic subunit and BAF250A/ARID1A, BAF250B/
ARID1B, or BAF180/BRM1, which contain ARID and 
bromodomains that bind to DNA and acetylated histones, 
respectively. Several genetically-engineered mouse 
models support the human data. For example, although 
Brg1 constitutive null homozygotes are embryonic lethal, 
heterozygotes develop mammary tumors without exposure 
to any oncogenic agents [10, 11]. In this model, BRG1 is 
a haploinsufficient tumor suppressor as the tumors do not 
undergo loss of heterozygosity (LOH) and the wild-type 
allele is not silenced.
An important challenge is to understand the 
mechanism of SWI/SNF-mediated tumor suppression. 
SWI/SNF complexes have been studied primarily in 
the context of transcriptional regulation, and several 
tumor-suppressor and proto-oncogene targets have been 
identified. For example, BRG1 and SNF5/BAF47 bind 
to the promoters of the p16INK4a and p21CIP/WAP1 cyclin-
dependent kinase (CDK) inhibitors and activate their 
expression in tumor-derived cell lines [12–16]. SWI/
SNF has also been linked to nuclear-hormone receptor 
signaling, the hedgehog-GLI pathway, RB and E2F1, 
CD44 and c-MYC in vitro [7], but it is currently unclear 
whether any of these targets are relevant for tumor 
suppression in vivo.
Because SWI/SNF complexes are chromatin 
remodelers, they are undoubtedly important for DNA-
templated processes other than transcription such as 
DNA replication and DNA repair. However, these 
fundamental processes have not been investigated 
adequately due to technical limitations. In contrast 
to transcriptional studies, where ChIP and ChIP-seq 
experiments have documented the occupancy of BRG1 
and other SWI/SNF subunits at enhancers and promoters 
of target genes in various cell types, this methodology 
is not appropriate for DNA replication/repair studies. 
The fact that DNA replication and DNA repair occur 
at different genomic sites in different cells within a 
population at any given time results in a lack of discrete 
peaks and precludes ChIP and related (e.g., FAIRE) 
methods. However, consistent with the proposed role(s) 
of SWI/SNF in DNA replication/repair, we previously 
demonstrated that BRG1 co-IPs and co-localizes with 
components of the DNA replication machinery such as 
the GINS complex, PCNA (proliferating cell nuclear 
antigen), and TOPBP1 (topoisomerase II-binding 
protein 1) during S phase [17]. More importantly, 
this study also demonstrated that perturbation of both 
SWI/SNF catalytic subunits (BRG1 and BRM) in 
mouse embryos or D98 tissue-culture cells results 
in a ~50% reduction in the efficiency of replication 
fork progression, which phenocopies RNAi-mediated 
knockdowns of Chk1, timeless, and claspin [18, 19]. 
This finding suggests that there might be a functional 
relationship between SWI/SNF and the DNA-damage 
response (DDR) or the replication fork protection 
complex (RFPC) and has implications for tumorigenesis 
because collapsed replication forks are a major driver 
of genomic instability [20]. Indeed, our Brg1+/null mouse 
model of breast cancer has mammary tumors with 
extensive copy-number gains (i.e., duplications and 
amplifications) and losses (i.e., deletions) [11].
The DDR is a cellular surveillance system that 
senses DNA damage and elicits an appropriate response 
that includes DNA repair or apoptosis to prevent genomic 
instability and cancer [21–24]. The DDR also regulates 
CDKs and checkpoints to delay or arrest cell-cycle 
progression and stabilize replication forks until the DNA 
damage has been bypassed or repaired, and this is crucial 
to prevent genomic instability. Not surprisingly, mutations 
of human DDR genes cause a number of genetic diseases/
syndromes and cancer [21]. The DDR, which has been 
conserved from yeast to humans, can be divided into 
two major pathways that respond to different types of 
DNA damage although there is some overlap. First, the 
PI3 kinase family member ATM (ataxia telangiectasia 
mutated) senses double-strand breaks (DSBs) induced 
by ionizing radiation (IR) and activates many targets 
including the Chk2 checkpoint kinase and the histone 
variant H2AX. Second, another member of the PI3 kinase 
family, ATR (ATM- and Rad3-related), senses excess RPA 
(replication protein A)-coated ssDNA that arises during 
S phase because of stalled replication forks. Stalling 
occurs in response to endogenous lesions and a variety 
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of genotoxic agents (e.g., ultraviolet light, PARP and 
topoisomerase inhibitors, and aphidicolin) and involves 
uncoupling of the MCM helicase and DNA Polymerase. 
Recruitment of ATR to a stalled fork by ATRIP (ATR-
interacting protein) binding to RPA kickstarts a DDR 
signaling pathway mediated, in part, by the replication 
fork protection complex (RFPC, which includes TIM-
TIPIN dimers and claspin) and γH2AX induction, and 
is transduced by the phosphorylation/activation of the 
checkpoint kinase Chk1. This culminates in activation 
of the intra-S phase checkpoint, which inhibits origin 
initiation and decreases the rate of active replication forks, 
until the DNA damage is bypassed or repaired [21–24]. 
The ATR signaling cascade prevents the collapse of stalled 
forks, which results in DSBs that cannot be repaired 
by DNA replication restart and can lead to genomic 
instability.
Considering the importance of SWI/SNF complexes 
in tumor suppression, it is surprising how little we know 
about their potential role in the DDR. To address this 
important issue, we have investigated the DDR in D98 
tissue-culture cells because of their ability to survive 
when BRG1 and BRM are simultaneously depleted using 
shRNAs [17]. D98 cells are physiologically relevant 
because they are derived from a cervical carcinoma (they 
are a HeLa cell subline) [25], and SWI/SNF subunits are 
mutated or silenced in cervical and uterine/endometrial 
tumors from mouse models and humans [26–29]. D98 cells 
are advantageous compared to primary cervical/uterine 
tumors because they are homogeneous and can be exposed 
to genotoxic agents in a rigorously controlled manner.
RESULTS
SWI/SNF protects against cell lethality induced 
by certain genotoxic agents that cause DSBs 
associated with DNA replication but not IR
To perturb the function of SWI/SNF complexes in 
D98 cells, the BRG1 and BRM catalytic subunits were 
simultaneously depleted by constitutive expression 
of shRNAs. Western blot analyses demonstrated that 
BRG1 and BRM were depleted to 8% and 16% of wild-
type levels, respectively (Fig. 1). Next, we exposed D98 
control cells and shRNA knockdown cells to a panel 
of genotoxic agents. We began with ABT-888, which 
is a poly(ADP-ribose) polymerase (PARP) inhibitor, 
because BRG1 co-immunoprecipitates with PARP1 
[30, 31]. PARP is a component of the base excision 
repair (BER) pathway and repairs single-strand breaks 
(SSBs) that arise during the repair of endogenous base 
damage such as abasic sites. PARP inhibitors lead to 
the persistence of SSBs [32]. When encountered by 
replication forks during DNA replication, SSBs are 
often converted to double-strand breaks (DSBs). The 
potential lethality of DSBs is increased dramatically 
if BRCA1 or other components of homologous 
recombination repair are mutated or silenced [33, 34]. In 
addition to interacting with PARP, components of SWI/
SNF complexes, including BRG1, interact with BRCA1 
[35–37]. Although the interaction between SWI/SNF 
complexes with PARP or BRCA1 has been studied in 
the context of transcriptional regulation, little is known 
Figure 1: Simultaneous depletion of both SWI/SNF catalytic subunits in D98 cells. Western blot analysis of BRG1, BRM, and 
tubulin loading control of D98 control cells and shRNA knockdown cells. After normalizing protein levels to tubulin, % BRG1 and % BRM 
refer to the amount of protein remaining in the cells expressing shRNAs compared to the control cell line.
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about how these interactions might affect DNA repair. 
Compared to the control cells, the shRNA knockdown 
cells were hypersensitive to ABT-888. The SF70 (dosage 
at which 70% of cells survived) was 100 μM for the 
control cells but only 3.5 μM for the RNAi knockdown 
cells (Fig. 2A). The SF50 was not reached in the control 
cells even at the highest dose (100 μM), which indicates 
ABT-888 was not very cytotoxic, while the SF50 was 
25 μM for shRNA knockdown cells.
Inhibition of topoisomerase I can also result in SSBs 
being converted to lethal DSBs during DNA replication 
[38], so we hypothesized that the shRNA knockdown cells 
would also exhibit increased sensitivity to camptothecin. 
Similar to treatment with ABT-888, shRNA knockdown 
cells were hypersensitive to camptothecin. For camp-
tothecin, the SF50 was 11.5 nM and 6 nM for the control 
cells and shRNA knockdown cells, respectively (Fig. 2B).
We performed NADPH assays, which provide a 
quantitative measurement of SSBs [39], and the shRNA 
knockdown cells did not have an increased number of 
SSBs either under basal conditions or in response to 
the alkylating agent methyl methane sulfonate (MMS) 
(Supplementary Fig. 1). This result suggests that the 
increased susceptibility of shRNA knockdown cells to 
PARP and camptothecin is not due to a higher number 
of SSBs to begin with but is instead due to an increased 
conversion of SSBs to DSBs.
Considering that cells deficient for SWI/SNF 
function appeared to be hypersensitive to genotoxic 
agents that increase the probability of generating DSBs 
at replication forks, we examined whether SWI/SNF 
complexes were required exclusively for survival 
from replication-dependent DSBs or DSBs in general. 
Interestingly, cells depleted of BRG1 and BRM were 
not hypersensitive to ionizing radiation (IR) (Fig. 2C) 
but were hypersensitive to etoposide (Fig. 2D), which 
inhibits topoisomerase II, an enzyme that induces DSBs to 
decatenate sister chromatids in S phase and G2 of the cell 
cycle. For etoposide, the SF50 was 490 nM and 125 nM for 
the control cells and shRNA knockdown cells, respectively 
(Fig. 2D).
We also subjected D98 cells to ultraviolet 
light-C (UV-C), which stalls DNA replication forks 
by inducing the formation of DNA lesions such as 
cyclobutane pyrimidine dimers and 6,4 photoproducts, 
and aphidicolin, which stalls DNA replication forks by 
inhibiting replicative DNA polymerases. Cells deficient 
for SWI/SNF complex activity were not hypersensitive 
to these replication fork-stalling agents (Fig. 2E and 
2F). Lastly, we analyzed annexin V straining as an early 
marker of apoptosis and PI staining as a measure of 
DNA content and cell-cycle progression (Supplementary 
Fig. 2–3). UV, IR, and etoposide induced apoptosis by 
approximately 2-fold and altered the cell cycle within 1 hr 
of exposure, which is consistent with the genotoxicity of 
these agents.
SWI/SNF complexes promote full activation of 
the DDR
ATM and ATR are kinases that initiate complex 
signaling cascades in response to DNA damage [40], and 
Chk1 kinase, Chk2 kinase, and the histone variant H2AX are 
key phosphorylation targets of ATM and ATR. To determine 
whether SWI/SNF is required for the DDR, we assessed 
activation of the ATM-Chk2 and ATR-Chk1 signaling 
pathways. We exposed control D98 cells and shRNA 
knockdown cells to different doses of genotoxic agents and 
performed western blot analyses to detect P-ATM S1981, 
P-Chk1 S345, and P-Chk2 T68 (Fig. 3). The activated 
phospho-protein levels were normalized to total ATM, 
Chk1, or Chk2 and presented as their level of induction 
over control treatment alone (Fig. 4). As expected, each 
genotoxic agent stimulated the DDR in a dose-dependent 
manner, and P-ATM, P-Chk1, and P-Chk2 were induced to 
different extents depending on the genotoxic agent (Figs. 3 
and 4). For example, aphidicolin induced P-Chk1 up to 25 
fold but did not induce either P-ATM or P-Chk2, which is 
consistent with aphidicolin causing replication forks to stall 
and triggering the ATR arm of the DDR. On the other hand, 
IR induced P-ATM and P-Chk2 by up to 16 and 20 fold, 
whereas it induced P-Chk1 to a lesser extent (up to 8 fold). 
This is compatible with IR causing DSBs independent of 
DNA replication and primarily triggering the P-ATM arm of 
the DDR. These observations suggest that DDR activation 
is normal in D98 control cells. Overall, deficiency for SWI/
SNF complexes reduced genotoxin-dependent activation of 
key DNA damage-response kinases by approximately 50%. 
However, SWI/SNF complexes did not appear to contribute 
to DDR activation in response to IR.
SWI/SNF is required for maximal γH2AX levels 
in a genotoxin-specific manner
When ATM, ATR, and DNA-PK are activated, they 
can phosphorylate the histone variant H2AX at Ser139 
(γH2AX) at damaged sites, which is an important, early 
event in the DDR. The BRG1 catalytic subunit has been 
implicated in γH2AX regulation [41, 42] so we compared 
γH2AX levels to total H2AX levels in the D98 control cells 
and shRNA knockdown cells. Camptothecin, etoposide, 
UV-C, and IR induced γH2AX in a dose-dependent manner 
that did not differ between control cells and shRNA 
knockdown cells (Supplementary Fig. 4). Surprisingly, 
however, induction of γH2AX was significantly attenuated 
in shRNA knockdown cells only in response to etoposide 
(Fig. 5A and 5B). The reason for this specificity is not 
known, but it does correlate with etoposide having the 
largest induction of P-ATM in control cells and the most 
attenuated P-ATM induction in shRNA knockdown 
cells. It is also consistent with recently reported links 
between SWI/SNF and topoisomerase II α (TOP2A) and 
topoisomerase II-binding protein 1 (TOPBP1) [17, 43].
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Figure 2: Dose-response survival curves of D98 control cells and shRNA knockdown cells after being exposed to 
various genotoxic agents. Each data point represents the mean ± standard deviation for three replicates. The legend displays the SF50 
dose for controls and shRNA cells. SF70 values are provided when the SF50 is not reached in control cells.
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SWI/SNF is required for proper genome 
segregation
One might expect an impaired DDR to result in 
genomic instability. Although the D98 knockdown cells 
grew slowly compared to controls, we did not observe 
chromosomal aberrations, micronuclei, or other nuclear 
anomalies at levels greater than the parental line (data not 
shown), presumably because this is a HeLa cell subline 
with an unusual karyotype that has mutations that preclude 
further genomic instability. Therefore, we depleted BRG1 
and/or BRM in normal human fibroblasts (NHF1-hTERT), 
Figure 3: Activation of DDR proteins in D98 control cells versus shRNA knockdown cells (shRNAs) after exposure to 
genotoxic agents. Western blots are shown for P-ATM S1981 and total ATM, P-Chk1 S345 and total Chk1, and P-Chk2 T68 and total 
Chk2. Genotoxic agents are shown below the western blot panels, and the doses are shown above each lane. The results are representative 
of 3 independent experiments.
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Figure 4: Attenuated induction of DDR protein phosphorylation in shRNA knockdown cells. Quantification of P-Chk1 
S345, P-ATM S1981, and P-Chk2 T68 levels normalized to total protein levels of each protein. The values correspond to the fold increase 
for each dose compared to vehicle-treated controls. Each panel corresponds to treatment with a different genotoxic agent (listed above) and 
shows controls (Cntrl) to the left and shRNA knockdown cells (shRNAs) to the right.
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which have been immortalized with hTERT but are non-
transformed and have normal karyotypes and an intact 
DDR and cell-cycle checkpoints [44, 45]. Western blot 
analyses confirmed a robust knockdown in each case and 
also revealed elevated BRM protein levels in siBRG1 cells 
that were approximately 150–200% relative to controls 
(Fig. 6A). The converse situation has long been known 
to occur, where BRG1 protein levels are upregulated 
in BRM-deficient cells [46], but this finding confirms 
a recent report that BRM can be upregulated in BRG1-
deficient cells [47]. This finding suggests that BRG1 and 
BRM functionally compensate in NHF1-hTERT as they 
do in mouse embryos [48] and adult vascular endothelial 
cells [49]. Indeed, NHF1-hTERT depleted of BRG1 or 
BRM grew normally in colony forming assays, whereas 
cells depleted of both BRG1 and BRM formed colonies at 
only 30% of controls (Fig. 6B). Similar to the D98 cells, 
the double-knockdown NHF1-hTERT did not show signs 
of spontaneous chromosomal instability based on Giemsa-
stained metaphase spreads (data not shown). However, 
they did show signs of aberrant nuclear morphology 
with the formation of buds, blebs, and necks (Fig. 6C). 
DAPI staining confirmed the presence of nucleoplasmic 
bridges in the neck structures (Supplementary Fig. 5). 
Quantification of these results demonstrated the presence 
of these aberrant nuclei in approximately 9% of double-
knockdown cells, which was 10-fold higher than the 
control cells (Fig. 6D). However, despite this severe 
spontaneous phenotype, we did not observe an impaired 
DDR in double-knockdown NHF1-hTERT based on 
P-ATM and P-Chk2 expression in response to IR or 
P-Chk1 expression in response to UV-C (Fig. 6E).
DISCUSSION
The results presented here demonstrate that SWI/
SNF chromatin-remodeling complexes are required for 
the full activation of the DDR. In our experiments, the 
phosphorylation status of checkpoint proteins in the DDR 
was assessed 30–60 minutes after control or knockdown 
Figure 5: Attenuated induction γ-H2AX in D98 control cells versus shRNA knockdown cells after exposure to 
etoposide. (A) Western blots showing γH2AX and total H2AX as a loading control. Etoposide doses are shown above each lane. 
(B) Relative levels of γH2AX normalized to total H2AX.
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Figure 6: Depletion of the SWI/SNF catalytic subunits in NHF1-hTERT cells and functional outcomes. (A) Western blot 
analysis of BRG1, BRM, and tubulin loading control in NHF1-hTERT cells transfected with the following siRNAs as indicated above each 
lane: NTC (non-targeted control), BRG1, BRM, or BRG1 and BRM simultaneously. Protein lysates were prepared 72 hours (left) or 96 
hours (right) after electroporation of the siRNAs. Shown below each lane is the quantification of BRG1 and BRM protein levels normalized 
to tubulin. Protein levels in siBRG1 and/or siBRM cells are shown as a percentage of controls (which are set at 100). (B) Colony formation 
assays of NHF1-hTERT depleted of BRG1 or BRM, or both SWI/SNF catalytic subunits. Histograms show the mean ± standard deviation 
based on 3 independent experiments. (C) Representative images of normal nuclei and nuclei with buds, blebs, and necks. 100X magnification. 
(D) Quantification of nuclei with buds, blebs, and necks in NTC siRNA cells and double-knockdown cells (BRG1 + BRM siRNAs) at 72 
hours and 96 hours after electroporation of siRNAs. (E) Activation of DDR proteins in NHF1-hTERT cells with RNAi-mediated knockdown 
of nontargeted control (NTC), BRG1, BRM, or BRG1 and BRM simultaneously. Western blots are shown for P-ATM S1981 and total 
ATM, P-Chk2 T68 and total Chk2, and P-Chk1 S345 and total Chk1. IR and UVC treatments are shown above each lane. The results are 
representative of 2–3 independent experiments.
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cells were exposed to genotoxic or fork-stalling agents. 
Such rapid kinetics strongly suggests that SWI/SNF plays 
a direct role at damaged sites rather than an indirect role 
meditated via transcriptional regulation of DNA repair 
factors. A direct role for SWI/SNF in the DDR is also 
supported by a proteomic screen that identified BRG1, 
BRM, and other SWI/SNF subunits as targets of ATM and 
ATR phosphorylation in response to IR or UV treatment 
[50]. Recently, a direct link between ATM and BRG1 
phosphorylation was confirmed [51]. At a functional 
level, RNAi has been performed to demonstrate that the 
BAF60A subunit (also known as SMARCD1) is important 
for γH2AX induction and cell-cycle arrest in response 
to IR [50]. It also has been reported that BRM plays a 
role in the intra-S phase checkpoint as Brm-/-fibroblasts 
continue to undergo DNA replication and cell proliferation 
following IR [46]. A role for SWI/SNF in the DDR would 
explain why it has been implicated in multiple types of 
DNA repair including nucleotide excision repair, non-
homologous end-joining, and homologous recombination 
[41, 42, 52–61]. It should be noted that some of these 
studies have reported functional differences, which is 
likely due to the comparison of cell lines derived from 
different tissue/tumor types that each have a unique 
genetic background. For example, BRG1 and BRM 
depletion had a much stronger effect on the survival of 
lung cancer cells [62] than what we observed for cervical 
cancer cells in this study.
In our experiments, SWI/SNF was important for 
full activation of ATM- and ATR-dependent responses 
of D98 cells to exogenous DNA damaging agents. This 
effect was also cell-type specific because SWI/SNF did 
not have the same effect in NHF1-hTERT cells. The 
DDR initiates signaling cascades that protect against 
replicative stress and genomic instability. Although we 
did not observe chromosomal aberrations in D98 cells or 
NHF1-hTERT depleted of BRG1 and BRM, we observed 
nucleoplasmic bridges in our knockdown NHF1-hTERT 
cells. These findings support previous observations where 
perturbation of the BRG1 catalytic subunit in ES cells, 
fibroblasts, and mammary epithelial cells resulted in 
aberrant nuclear morphology, anaphase bridge formation 
(in which sister chromatids are linked by catenated 
strands of DNA), micronuclei, and aneuploidy [43, 63–
65]. A similar phenotype has been reported for SNF5-
deficient mouse embryo fibroblasts (MEFs) [66]. DNA 
bridges can be severed during cytokinesis [67], which 
often results in partial or complete chromosomal gains 
or losses. Segregation defects also occur in vivo based 
on the extensive copy number gains and losses that were 
previously observed by array CGH in mammary tumors 
from our Brg1 mouse model of breast cancer [11]. The cause 
of aberrant nuclear morphology in cells deficient for SWI/
SNF catalytic subunits remains to be fully characterized, but 
it could be due in part to attenuation of the DDR.
Our results combined with these previous studies 
support the idea that SWI/SNF tumor suppression 
involves the maintenance of genomic stability. A recent 
study proposed a model for the molecular mechanism 
where SWI/SNF physically interacts with TOP2A 
and that BRG1 ATPase activity is required for TOP2A 
to bind chromatin [43]. This is compatible with our 
observation that SWI/SNF is required for the activation 
of ATM in response to etoposide but not other genotoxic 
agents. This model is also consistent with our previous 
findings that BRG1 co-immunoprecipitates (co-IPs) with 
TOPBP1 [17]. A link between SWI/SNF and TOP2A 
function might also be expected to apply to normal DNA 
replication during development. This is certainly the case 
for BRG1 and SWI/SNF, which are required for efficient 
replication fork progression and embryonic survival 
[10, 17], and is undoubtedly true for TOP2A function 
as well. Although Top2a knockout mice have not been 
described, Topbp1 knockouts die at the same early stage 
of embryogenesis as Brg1 null homozygotes [68], and 
TOPBP1 is involved in normal DNA replication as well 
as cancer prevention [69].
An unexpected but important aspect of our 
study is that SWI/SNF-deficient cells are specifically 
hypersensitive to PARP and topoisomerase inhibitors 
that induce the formation of highly supercoiled DNA 
between a frozen topoisomerase enzyme and a replication 
complex. This common feature, which is not shared by 
any of the other genotoxic agents that were utilized, 
suggests that SWI/SNF chromatin remodeling is required 
to bypass these structures. This might represent a major 
mechanism of SWI/SNF in the DDR. Lastly, the results 
of our cytotoxicity experiments suggest that knowing the 
status of SWI/SNF functionality in tumors could allow for 
better selection of anticancer chemotherapeutic treatment. 
These findings suggest that SWI/SNF mutant tumors will 
respond better to PARP and topoisomerase inhibitors than 
cisplatin or IR in the clinical setting.
METHODS
Cell culture
The D98 HeLa knockdown cells, which have 
marked reductions of BRG1 and BRM, have been 
described and validated previously [17]. Briefly, the 
cells were grown under puromycin (2 μg/ml) and G418 
(1 μg/ml) selection in RPMI supplemented with 10% 
FBS to maintain expression of stably integrated BRG1 
and BRM shRNA constructs, respectively. NHF1-hTERT 
cells were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 2 mM L-glutamine and 10% 
fetal bovine serum. Cell culture reagents were obtained 
from Sigma-Aldrich, and cells were grown at 37°C in a 
humidified atmosphere of 5% CO2.
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Exposure to genotoxic agents
For exposure to UV-C, cell culture medium was 
reserved, cells were washed with 37°C PBS, PBS was 
aspirated, and cells were exposed to UV-C or placed 
into the exposure chamber without exposure (control). 
Reserved cell culture medium was returned to the dishes 
and cells were incubated for 45 min before harvest. Cells 
were exposed to ionizing radiation using an RS2000 
Biological Irradiator (Rad-Source). Cells were harvested 
30 min after exposure. Cells were exposed to chemicals 
for one hour and concurrent controls exposed to the 
appropriate solvent were used for each experiment. The 
concentration of DMSO in cell culture medium did not 
exceed 0.1%.
D98 cell survival assays
D98 cell survival was assessed in triplicate in the 
absence of selection by plating ~2.5 x 103 cells in 250 
μL per well in 24-well plates and exposing to ABT-
888, camptothecin, etopocide, cisplatin, MMS, UV-C, 
aphidicolin, or IR. After 3 days, cells were cultivated and 
viability was determined by the XTT assay [70, 71].
Western blot analyses
At the time of harvest, cell culture medium 
was aspirated, cells were washed with PBS, and were 
detached from dishes by trypsin. Trypsinization was 
stopped with medium containing 10% FBS, and cells 
were spun down and washed once with ice-cold PBS. 
Cells were counted using a Coulter counter (Beckman 
Coulter) and re-suspended in a volume of 2X SDS 
lysis buffer (62.5 mM Tris-Cl pH 6.8, 2% SDS, 25% 
glycerol, and 0.01% bromophenol blue with 10% 
β-mercaptoethanol added at the time of use) for a 
concentration of 1 million cells/100 μl buffer. Protein 
lysates were boiled for 10 min and stored at ˗80°C. Equal 
volumes of protein lysates were run per well in pre-
cast protein electrophoresis gradient gels (BioRad) and 
proteins were transferred onto nitrocellulose membranes 
(BioRad). Membranes were blocked with 5% BSA 
(for detection of phospho-proteins) or 5% milk before 
application of primary antibodies. The antibodies used 
in this study were rabbit anti-BRM (Abcam, ab15597), 
mouse anti-BRG1 (Santa Cruz Biotechnology, sc-17796/
G7), mouse anti-α-tubulin (Sigma, T6199, rabbit anti-P-
ATM S1981 (Epitomics, EP1890Y), rabbit anti-P-Chk2 
(Cell Signaling, 2661), rabbit anti-P-Chk1 S345 (Cell 
Signaling, 2348), mouse anti-γ-H2AX S139 (Millipore, 
05–636), rabbit anti-ATM (Bethyl, A300-299A-2), mouse 
anti-Chk2 (BD Biosciences, 611570), mouse anti-Chk1 
(Santa Cruz, sc-8408), and rabbit anti-H2AX (Millipore, 
07–627). When applicable, membranes were probed 
first with phospho-antibodies, stripped, and re-probed 
for total protein. Image J software was used to quantify 
signals (Rasband, WS, Image J US National Institute 
of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/). 
Levels of BRG1 or BRM were normalized to α-tubulin, 
and phospho-proteins were normalized to their respective 
total protein levels.
Protein depletion by siRNA
NHF1-hTERT were electroporated with siRNAs 
using the normal human dermal fibroblast nucleofection 
kit VPD-1001 (Lonzo) and electroporation program 
U-23. The total amount of siRNA introduced into cells 
for single versus double depletions was held constant 
at 200 pmol siRNA per 1 million cells (100 pmol of 
targeting siRNA was combined with 100 pmol of NTC 
siRNA for single depletions). siGENOME Smart Pool 
siRNAs were purchased from Dharmacon to deplete 
BRG1 (M-010431) or BRM (M-017253). Non-targeted 
control (NTC) siRNA (D001206) was also obtained from 
Dharmacon.
Clonogenic survival assays
The clonogenic survival assays were performed as 
previously described [72]. Briefly, NHF1-hTERT cells 
electroporated with siRNAs were seeded at a density that 
would result in ~150 colonies per 10 cm dish for the 
NTC siRNA control. Each independent experiment was 
seeded in triplicate, and the experiment was repeated 
two to three times per siRNA. Cells were stained in a 
solution of 0.05% Crystal Violet in 40% methanol on 
day 14 after seeding. Colonies of 50 cells or more were 
counted.
Metaphase preparations
Giemsa-stained metaphases were prepared as 
previously described [72]. Briefly, 50 metaphases with 
bifilar sister chromatids were evaluated per treatment. For 
measures of nuclear abnormalities, approximately 1,000 
nuclei were examined per treatment. The experimenter 
was blind to treatment during the collection of data 
and analysis of chromosomal aberrations and nuclear 
abnormalities.
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